Diabetic Foot News and Research

RSS

SANUWAVE second quarter revenues increase 40%

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

10 Aug 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011

Derma Sciences announces $29 million financing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously announced private placement.

27 Jun 2011

Derma Sciences to raise $29M through private placement

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has entered into definitive agreements with select institutional investors to raise gross proceeds of approximately $29 million.

20 Jun 2011

LWW sponsors 26th Annual Clinical Symposium on Advances in Skin & Wound Care

The 26th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 9-12, 2011, at the Gaylord National Hotel & Convention Center, National Harbor, MD.

7 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.

25 May 2011

Resection arthroplasty more effective for patients with diabetic foot ulcers

A recent study published in the March issue of Foot & Ankle International, the official scientific journal of the American Orthopaedic Foot & Ankle Society describes a possible amputation alternative for patients with neuropathic ulceration of the first metatarsophalangeal or big toe joint.

28 Apr 2011

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

18 Apr 2011

ULURU fourth quarter net loss decreases to $0.3 million

ULURU Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010.

1 Apr 2011

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.

30 Mar 2011

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that one of its indirect subsidiaries has signed a definitive agreement to purchase Rikco International, LLC, D/B/A Dr. Comfort, for approximately $254.6 million in cash.

15 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.

23 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

8 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

7 Feb 2011

SANUWAVE Health raises $4,102,660 from exercise of Options

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, announces that it has raised gross proceeds of $4,102,660 from the exercise of Options that were issued as part of the sale of Units to accredited investors during 2010. The Options had an expiration date of January 31, 2011.

7 Feb 2011

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).

4 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011

Diabetic Foot News and Research

SANUWAVE second quarter revenues increase 40%

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Derma Sciences announces $29 million financing

Derma Sciences to raise $29M through private placement

LWW sponsors 26th Annual Clinical Symposium on Advances in Skin & Wound Care

Bharat Biotech announces the pricing for ROTAVAC vaccine

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Resection arthroplasty more effective for patients with diabetic foot ulcers

CoDa Therapeutics raises $19.2 million in Series B financing

ULURU fourth quarter net loss decreases to $0.3 million

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

SANUWAVE Health raises $4,102,660 from exercise of Options

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News